Aveanna Healthcare (NASDAQ:AVAH) Releases Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Aveanna Healthcare (NASDAQ:AVAH) released its earnings results on Thursday. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.02, FiscalAI reports. Aveanna Healthcare had a net margin of 10.56% and a return on equity of 80.70%. The business had revenue of $695.54 million for the quarter, compared to analysts’ expectations of $679.48 million.

Here are the key takeaways from Aveanna Healthcare’s conference call:

• Aveanna reported Q3 revenue of $695.5 million, up 11.8%, and adjusted EBITDA of $100.1 million, up 25% year over year. Management raised 2026 guidance to revenue above $2.695 billion and adjusted EBITDA above $374 million.
• Growth was broad-based, with all three segments reporting higher revenue; Home Health and Hospice grew 15.6%, supported by 19.6% more admissions and 24% more episodes. Management raised its long-term organic growth outlook for Private Duty Services to 5%–6% and Home Health and Hospice to 8%–10%, while reaffirming 8%–10% for Medical Solutions.
• California’s planned $60 million PDN rate investment is currently viewed by the state as a supplemental payment for only the first half of 2027, while Aveanna is advocating for it to become permanent. The company said it will not make meaningful base-wage increases for California nurses until it has more certainty about ongoing reimbursement.
• Year-to-date operating cash flow was $157.5 million and free cash flow was $141.2 million; liquidity totaled $492 million, and the company said substantially all variable-rate debt is hedged through December 2029. Aveanna plans to pursue acquisitions while targeting leverage below 3x in 2027.
• Management expects Q4 to be seasonally choppy around the holidays and noted that Q4 2025 had an extra week, making year-over-year comparisons tougher. It said a mid-$90 million range is a prudent Q4 adjusted EBITDA planning anchor.

Aveanna Healthcare Stock Down 5.6%

NASDAQ AVAH traded down $0.74 during trading hours on Thursday, hitting $12.35. The company had a trading volume of 3,087,288 shares, compared to its average volume of 2,036,686. Aveanna Healthcare has a fifty-two week low of $5.93 and a fifty-two week high of $14.71. The company has a market capitalization of $2.70 billion, a price-to-earnings ratio of 10.04, a P/E/G ratio of 0.81 and a beta of 2.03. The company has a debt-to-equity ratio of 4.47, a current ratio of 1.16 and a quick ratio of 1.16. The firm’s 50 day moving average is $13.08 and its 200 day moving average is $9.43.

Insider Buying and Selling

In other Aveanna Healthcare news, major shareholder J.H. Whitney Equity Partners V sold 12,496,077 shares of the business’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $11.50, for a total transaction of $143,704,885.50. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Paul Vigano sold 14,500,002 shares of the company’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $11.50, for a total value of $166,750,023.00. The SEC filing for this sale provides additional information. Insiders sold a total of 48,566,081 shares of company stock valued at $558,509,932 over the last ninety days. Insiders own 5.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. JPMorgan Chase & Co. lifted their price target on shares of Aveanna Healthcare from $8.00 to $15.00 and gave the company a “neutral” rating in a report on Monday, September 14th. Weiss Ratings raised Aveanna Healthcare from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Wednesday, October 14th. BMO Capital Markets lifted their target price on Aveanna Healthcare from $10.00 to $14.00 and gave the company an “outperform” rating in a report on Friday, August 14th. Raymond James Financial reissued a “strong-buy” rating on shares of Aveanna Healthcare in a research report on Thursday. Finally, Barclays upped their price target on Aveanna Healthcare from $9.50 to $15.00 and gave the stock an “overweight” rating in a research note on Friday, August 28th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $14.25.

Latest Aveanna Healthcare News

Here’s some of the latest news about AVAH:

• Positive Sentiment: Aveanna earned $0.23 per share, topping the $0.21 consensus estimate and rising from $0.15 a year earlier. Revenue of $695.54 million also exceeded analysts’ $679.48 million estimate. Aveanna Healthcare Q3 Earnings and Revenues Beat Estimates
• Positive Sentiment: Coverage described the company’s revised 2026 guidance as raised, providing a potentially favorable signal about management’s outlook. Aveanna Healthcare Q3 2026: EPS Beats, Guidance Raised
• Neutral Sentiment: The company’s FY 2026 revenue guidance was $2.7 billion, matching the consensus estimate. That may temper the upside from the quarterly beat if investors were looking for a larger forecast increase. Aveanna Announces Third Quarter Results and Revised 2026 Guidance

Aveanna Healthcare Company Profile

Aveanna Healthcare Holdings Inc. is a U.S. provider of home-based healthcare services for children and adults with complex medical needs. Its services include private-duty nursing and personal care, home health nursing and therapy, and hospice care, helping patients receive support in their homes and communities. The company also provides medical supplies and related services, including products used for enteral nutrition. Aveanna serves patients and families across multiple states through a network of clinicians, caregivers, and local operations.